← Back to Search


Sonobiopsy for Glioblastoma

Washington University School of Medicine, Saint Louis, MO
Targeting 2 different conditionsSonobiopsy +3 moreN/ARecruitingLed by Albert Kim, M.D.Research Sponsored by Washington University School of Medicine

Study Summary

This trial is important because it will help doctors understand how to best treat brain tumors by looking at their molecular features. Sonobiopsy has the potential to become a standard tool for diagnosing and managing brain tumors, which could dramatically improve patient outcomes.

Eligible Conditions
  • Glioblastoma

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
The abnormality being studied must be located in the upper part of the brain and within 5 cm of the outer layer.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Feasibility of sonobiopsy as measured by change in ctDNA level
Number of matched mutations between the post-sonobiopsy sample and the tumor tissue sample

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: SonobiopsyExperimental Treatment4 Interventions
Once enrolled, participants would be prepared for standard of care surgery. The sonobiopsy involves the standard procedure for a biopsy, but the biopsy needle is replaced with a customized ultrasound probe, a standard ultrasound contrast agent (microbubbles) is injected intravenously, and the probe is turned on for 3 minutes for the sonobiopsy. Then the planned surgery to remove the tumor will occur. An additional brief MRI scan will be obtained using the intraoperative MRI to define imaging changes (if any) that occur as a result of the sonobiopsy procedure. The imaging protocols will include a 3D T2-weighted (T2w) scan, and 3D contrast T1-weighted (T1w) with dynamic contrast enhancement and if time allows T2* sequence. Blood will be collected at several time points. A small skin biopsy or another blood draw will be drawn for comparison against the genetic mutations shown in the tumor. The blood, tumor, and skin (if applicable) will undergo genetic analysis.

Find a Location

Who is running the clinical trial?

Washington University School of MedicineLead Sponsor
1,900 Previous Clinical Trials
2,280,917 Total Patients Enrolled
17 Trials studying Glioblastoma
581 Patients Enrolled for Glioblastoma
National Cancer Institute (NCI)NIH
13,490 Previous Clinical Trials
41,266,675 Total Patients Enrolled
312 Trials studying Glioblastoma
22,593 Patients Enrolled for Glioblastoma
Albert Kim, M.D.Principal InvestigatorWashington University School of Medicine

Media Library

Sonobiopsy (Ultrasound) Clinical Trial Eligibility Overview. Trial Name: NCT05281731 — N/A
Glioblastoma Research Study Groups: Sonobiopsy
Glioblastoma Clinical Trial 2023: Sonobiopsy Highlights & Side Effects. Trial Name: NCT05281731 — N/A
Sonobiopsy (Ultrasound) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05281731 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are currently taking part in this research study?

"Affirmative. The clinicaltrial.gov registry states that this research program is actively seeking participants and was first listed on April 16th 2022. To date, the trial has enrolled 20 individuals at a single medical center."

Answered by AI

Is enrollment in this experiment ongoing?

"Confirmation of active recruitment is available on clinicaltrials.gov; this trial was initially made public on April 16th 2022 and the most recent update occurred September 21st of the same year."

Answered by AI
~18 spots leftby Apr 2025